Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies

Karmakar, Surojit; Pal, Pradipta; Lal, Girdhari

doi:10.2147/itt.s306109

Cited by 17 publications

(7 citation statements)

References 215 publications

(241 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NK cells - They show potent cytotoxic activity against cancer cells through the release of perforin and granzymes close to target cells or by receptor-induced target cell apoptosis, and they can also modulate the effector response of additional immune cells [ 119 , 120 ]. This latter NK function can be driven by melanoma-derived PGE 2 , which decreases viability and production of classical type 1 DC chemo-attractants by NK [ 121 ].…”

Section: Introductionmentioning

confidence: 99%

Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance

Vasseur

Guillaumond

2022

Oncogenesis

View full text Add to dashboard Cite

Lipids are essential constituents for malignant tumors, as they are absolutely required for tumor growth and dissemination. Provided by the tumor microenvironment (TME) or by cancer cells themselves through activation of de novo synthesis pathways, they orchestrate a large variety of pro-tumorigenic functions. Importantly, TME cells, especially immune cells, cancer-associated fibroblasts (CAFs) and cancer-associated adipocytes (CAAs), are also prone to changes in their lipid content, which hinder or promote tumor aggressiveness. In this review, we address the significant findings for lipid contribution in tumor progression towards a metastatic disease and in the poor response to therapeutic treatments. We also highlight the benefits of targeting lipid pathways in preclinical models to slow down metastasis development and overcome chemo-and immunotherapy resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance

Vasseur

Guillaumond

2022

Oncogenesis

View full text Add to dashboard Cite

show abstract

“…In an important early study by Miller et al, 19 AML patients received haploidentical NK cell infusions at doses up to 2 × 10 7 cells/kg with or without modified IL-2 injections, with five patients achieving a morphologic CR [61]. Three lymphodepletion regimens were evaluated in this trial, including two low dose outpatient regimens and a high dose inpatient regimen, the latter of which consisted of intravenous fludarabine 25 mg/m 2 and cyclophosphamide 60 mg/kg for five days.…”

Section: Peripheral Blood and Umbilical Cord Bloodmentioning

confidence: 97%

“…In addition, non-MHC-specific receptors such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte associated protein-4 (CTLA-4) can also have inhibitory properties on NK cell function [18]. Activating receptors include activating C-type lectin-like receptors (e.g., NK group 2D, or NKG2D, which binds inducible stress ligands), natural cytotoxicity receptors (e.g., NK p46-related protein, or NKp46), activating KIRs, and Fc-γ receptor IIIA (i.e., CD16) [19]. Importantly, CD16 binds to the Fc portion of immunoglobulin G (IgG) to activate antibody-dependent cellular cytotoxicity (ADCC) [20].…”

Section: Nk Cell Biologymentioning

confidence: 99%

Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond

Lin

Horwitz

Rein

2022

IJMS

View full text Add to dashboard Cite

Numerous recent advancements in T-cell based immunotherapies have revolutionized the treatment of hematologic malignancies. In the race towards the first approved allogeneic cellular therapy product, there is growing interest in utilizing natural killer (NK) cells as a platform for off-the-shelf cellular therapies due to their scalable manufacturing potential, potent anti-tumor efficacy, and superior safety profile. Allogeneic NK cell therapies are now being actively explored in the setting of hematopoietic stem cell transplantation and adoptive transfer. Increasingly sophisticated gene editing techniques have permitted the engineering of chimeric antigen receptors, ectopic cytokine expression, and tumor recognition signals to improve the overall cytotoxicity of NK cell therapies. Furthermore, the enhancement of antibody-dependent cellular cytotoxicity has been achieved through the use of NK cell engagers and combination regimens with monoclonal antibodies that act synergistically with CD16-expressing NK cells. Finally, a greater understanding of NK cell biology and the mechanisms of resistance have allowed the preclinical development of NK checkpoint blockade and methods to modulate the tumor microenvironment, which have been evaluated in early phase trials. This review will discuss the recent clinical advancements in NK cell therapies in hematologic malignancies as well as promising avenues of future research.

show abstract

“…In addition, ASFV infection of cells resulted in increased expression of SLA-DOA and SLA-DOB, which inhibited the binding of antigenic peptides to MHC-II [ 40 ]. However, ASFV can inhibit the expression of MHC-I, NK cells will not receive inhibitory signals, and cells infected with ASFV may be killed [ 57 ]. Similar to T cells, NK cells induce apoptosis by activating intracellular caspases cascades through both exogenous and endogenous pathways.…”

Section: The Major Defense Mechanisms and Asfv Interactionsmentioning

confidence: 99%

Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus

Wang

Huang

et al. 2022

Vaccines

View full text Add to dashboard Cite

African swine fever virus (ASFV) is the causative agent of the epidemic of African swine fever (ASF), with virulent strains having a mortality rate of up to 100% and presenting devastating impacts on animal farming. Since ASF was first reported in China in 2018, ASFV still exists and poses a potential threat to the current pig industry. Low-virulence and genotype I strains of ASFV have been reported in China, and the prevention and control of ASF is more complicated. Insufficient understanding of the interaction of ASFV with the host immune system hinders vaccine development. Physical barriers, nonspecific immune response and acquired immunity are the three barriers of the host against infection. To escape the innate immune response, ASFV invades monocytes/macrophages and dendritic cells, thereby inhibiting IFN expression, regulating cytokine expression and the body’s inflammatory response process. Meanwhile, in order to evade the adaptive immune response, ASFV inhibits antigen presentation, induces the production of non-neutralizing antibodies, and inhibits apoptosis. Recently, significant advances have been achieved in vaccine development around the world. Live attenuated vaccines (LAVs) based on artificially deleting specific virulence genes can achieve 100% homologous protection and partial heterologous protection. The key of subunit vaccines is identifying the combination of antigens that can effectively provide protection and selecting carriers that can effectively deliver the antigens. In this review, we introduce the epidemic trend of ASF and the impact on the pig industry, analyze the interaction mechanism between ASFV and the body’s immune system, and compare the current status of potential vaccines in order to provide a reference for the development of effective ASF vaccines.

show abstract

Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies

Cited by 17 publications

References 215 publications

Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance

Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance

Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond

Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus

Contact Info

Product

Resources

About